# A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects

> **NCT00937872** · PHASE1 · COMPLETED · sponsor: **Sirtris, a GSK Company** · enrollment: 9 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** 250 mg SRT2104 Suspension
- **DRUG:** Carbon-14 radio-labeled SRT2104

## Key facts

- **NCT ID:** NCT00937872
- **Lead sponsor:** Sirtris, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11-22
- **Primary completion:** 2008-12-22
- **Final completion:** 2008-12-22
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2017-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00937872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00937872, "A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00937872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*